The stock of Phio Pharmaceuticals Corp (PHIO) has seen a 8.60% increase in the past week, with a 14.83% gain in the past month, and a 98.35% flourish in the past quarter. The volatility ratio for the week is 6.71%, and the volatility levels for the past 30 days are at 9.96% for PHIO. The simple moving average for the last 20 days is -0.26% for PHIO stock, with a simple moving average of 5.27% for the last 200 days.
Is It Worth Investing in Phio Pharmaceuticals Corp (NASDAQ: PHIO) Right Now?
Company’s 36-month beta value is 0.85.Analysts have differing opinions on the stock, with 0 analysts rating it as a “buy”, 1 as “overweight”, 0 as “hold”, and 0 as “sell”.
The public float for PHIO is 4.73M, and currently, short sellers hold a 5.09% ratio of that floaft. The average trading volume of PHIO on July 04, 2025 was 3.36M shares.
PHIO stock’s latest price update
The stock of Phio Pharmaceuticals Corp (NASDAQ: PHIO) has decreased by -3.23% when compared to last closing price of $2.48. Despite this, the company has experienced a 8.60% gain in its stock price over the last five trading sessions. newsfilecorp.com reported 2025-06-25 that -Phio’s lead clinical siRNA compound PH-762 demonstrates supportive safety profile in fourth cohort, permitting dose escalation in expected final cohort Marlborough, Massachusetts–(Newsfile Corp. – June 25, 2025) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that the Safety Monitoring Committee (SMC) recommended dose escalation in its Phase 1b clinical trial designed to evaluate the safety and tolerability of intratumoral (IT) PH-762 in the treatment of Stages 1, 2, and 4 cutaneous squamous cell carcinoma (cSCC), Stage 4 melanoma, and Stage 4 Merkel cell carcinoma.
Analysts’ Opinion of PHIO
Many brokerage firms have already submitted their reports for PHIO stocks, with H.C. Wainwright repeating the rating for PHIO by listing it as a “Buy”. The predicted price for PHIO in the upcoming period, according to H.C. Wainwright is $14 based on the research report published on June 05, 2025 of the current year 2025.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see PHIO reach a price target of $4. The rating they have provided for PHIO stocks is “Buy” according to the report published on August 05th, 2020.
PHIO Trading at 13.48% from the 50-Day Moving Average
After a stumble in the market that brought PHIO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -75.49% of loss for the given period.
Volatility was left at 9.96%, however, over the last 30 days, the volatility rate increased by 6.71%, as shares surge +14.29% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -4.38% lower at present.
During the last 5 trading sessions, PHIO rose by +8.60%, which changed the moving average for the period of 200-days by -27.05% in comparison to the 20-day moving average, which settled at $2.41. In addition, Phio Pharmaceuticals Corp saw -60.30% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at PHIO starting from Bitterman Robert J, who purchase 2,000 shares at the price of $2.42 back on Jun 10 ’25. After this action, Bitterman Robert J now owns 27,149 shares of Phio Pharmaceuticals Corp, valued at $4,840 using the latest closing price.
Ferrara Robert L, the Director of Phio Pharmaceuticals Corp, purchase 2,500 shares at $2.42 during a trade that took place back on Jun 10 ’25, which means that Ferrara Robert L is holding 15,666 shares at $6,050 based on the most recent closing price.
Stock Fundamentals for PHIO
The total capital return value is set at -0.43%. Equity return is now at value -76.12%, with -66.67% for asset returns.
Currently, EBITDA for the company is -7.12 million with net debt to EBITDA at 2.6. The liquidity ratio also appears to be rather interesting for investors as it stands at 10.58.
Conclusion
In a nutshell, Phio Pharmaceuticals Corp (PHIO) has experienced a better performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
